RenaissThera, a Bengaluru, India-based biotechnology company for cardio-metabolic diseases, raised an undisclosed amount in Seed funding.
Backers included undisclosed angel investors.
The company intends to use the funds to accelerate the development of novel small-molecule therapies targeting GLP-1 and GIP receptors for Cardio-metabolic (CM) diseases, with an emphasis on diabetes and obesity.
Led by CEO Dr. Ramkesh Meena, RenaissThera is a biotechnology company dedicated to developing new small-molecule targeted therapies leveraging AI platforms. It focuses on high-unmet-need areas of prevalent diseases in key therapy areas such as Cardio-metabolic including diabetes and obesity indications leveraging its platform empowered by GenAI tools.
FinSMEs
10/12/2024